Windlas Biotech IPO oversubscribed 22.46 times on closing day

The initial public offer of Windlass Biotech, a manufacturer of pharmaceutical formulations, was subscribed 22.46 times on Friday, the closing day for subscription. The three-day IPO received bids for 13,77,39,750 shares against 61,36,252 shares on offer, as per NSE data. The category for Qualified Institutional Buyers(QIBs) was subscribed 24.40 times, non-institutional investors 15.73 times, and retail individual investors(RIIs) 24.27 times. The initial public offer had a fresh issue of up to Rs 165 crore and an offer for sale of up to 51,42,067 equity shares. The Rs 401.53-crore offer had a price range of Rs 448-460 per share. Windlas Biotech on Tuesday raised over Rs 120 crore from anchor investors. The proceeds from the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II. It will also be used for funding incremental working capi
06-08-2021

Subscribe to Windlas Biotech: Prabhudas Lilladher

Prabhudas Lilladher has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 05, 2021.
05-08-2021

Windlas Biotech offers its shares at 64x PE. Should you subscribe?

The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS).
04-08-2021
Close

Let's Open Free Demat Account